Cytosorbents Corporation - Common Stock — Quarterly Cash Flow (NASDAQ:CTSO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 50.78 M47.99 M45.75 M44.18 M40.56 M Total liabilities 36.24 M36.4 M36.73 M38.28 M38.37 M Total equity 14.54 M11.59 M9.02 M5.9 M2.19 M Total liabilities & shareholders' equities 50.78 M47.99 M45.75 M44.18 M40.56 M Total debt 14.19 M14.38 M14.57 M16.67 M10.31 M Net debt 14.19 M14.38 M14.57 M16.67 M10.31 M

News

Cytosorbents Corporation (CTSO) Presents at Life Sciences Virtual Investor Forum - Slideshow (NASDAQ:CTSO) 2026-06-27

CytoSorbents reports Q4 and full-year 2025 revenue expectations

Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript

Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript

Cytosorbents Crp earnings beat by $0.01, revenue fell short of estimates

Disney, Brookfield, Nu Holdings and more set to report earnings Thursday

CytoSorbents at H.C. Wainwright: Strategic Growth and Regulatory Challenges

Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Color Star Tech (NASDAQ:ADD), Aspen Insurance Hldgs (NYSE:AHL)

FDA upholds denial of CytoSorbents’ DrugSorb-ATR device, offers path forward

Cytosorbents stock plunges after regulatory setbacks for key device

CytoSorbents receives FDA appeal hearing date for DrugSorb-ATR device

CytoSorbents files appeal with FDA over denied device application